Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition letter

Gabrielle S. Wong, Jin Zhou, Jie Bin Liu, Zhong Wu, Xinsen Xu, Tianxia Li, David Xu, Steven E. Schumacher, Jens Puschhof, James McFarland, Charles Zou, Austin Dulak, Les Henderson, Peng Xu, Emily O'Day, Rachel Rendak, Wei Li Liao, Fabiola Cecchi, Todd Hembrough, Sarit SchwartzChristopher Szeto, Anil K. Rustgi, Kwok Kin Wong, J. Alan Diehl, Karin Jensen, Francesco Graziano, Annamaria Ruzzo, Shaunt Fereshetian, Philipp Mertins, Steven A. Carr, Rameen Beroukhim, Kenichi Nakamura, Eiji Oki, Masayuki Watanabe, Hideo Baba, Yu Imamura, Daniel Catenacci, Adam J. Bass

Research output: Contribution to journalArticle

Abstract

The role of KRAS, when activated through canonical mutations, has been well established in cancer 1 . Here we explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations. These amplifications occur most commonly in esophageal, gastric and ovarian adenocarcinomas 2-4 . KRAS-amplified gastric cancer models show marked overexpression of the KRAS protein and are insensitive to MAPK blockade owing to their capacity to adaptively respond by rapidly increasing KRAS-GTP levels. Here we demonstrate that inhibition of the guanine-exchange factors SOS1 and SOS2 or the protein tyrosine phosphatase SHP2 can attenuate this adaptive process and that targeting these factors, both genetically and pharmacologically, can enhance the sensitivity of KRAS-amplified models to MEK inhibition in both in vitro and in vivo settings. These data demonstrate the relevance of copy-number amplification as a mechanism of KRAS activation, and uncover the therapeutic potential for targeting of these tumors through combined SHP2 and MEK inhibition.

Original languageEnglish (US)
Pages (from-to)968-977
Number of pages10
JournalNature Medicine
Volume24
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Amplification
Chemical activation
Neoplasms
Mutation
Protein Tyrosine Phosphatases
Gene Amplification
Guanine
Guanosine Triphosphate
Stomach Neoplasms
Tumors
Stomach
Adenocarcinoma
Genes
Proteins
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition letter. / Wong, Gabrielle S.; Zhou, Jin; Liu, Jie Bin; Wu, Zhong; Xu, Xinsen; Li, Tianxia; Xu, David; Schumacher, Steven E.; Puschhof, Jens; McFarland, James; Zou, Charles; Dulak, Austin; Henderson, Les; Xu, Peng; O'Day, Emily; Rendak, Rachel; Liao, Wei Li; Cecchi, Fabiola; Hembrough, Todd; Schwartz, Sarit; Szeto, Christopher; Rustgi, Anil K.; Wong, Kwok Kin; Diehl, J. Alan; Jensen, Karin; Graziano, Francesco; Ruzzo, Annamaria; Fereshetian, Shaunt; Mertins, Philipp; Carr, Steven A.; Beroukhim, Rameen; Nakamura, Kenichi; Oki, Eiji; Watanabe, Masayuki; Baba, Hideo; Imamura, Yu; Catenacci, Daniel; Bass, Adam J.

In: Nature Medicine, Vol. 24, No. 7, 01.07.2018, p. 968-977.

Research output: Contribution to journalArticle

Wong, GS, Zhou, J, Liu, JB, Wu, Z, Xu, X, Li, T, Xu, D, Schumacher, SE, Puschhof, J, McFarland, J, Zou, C, Dulak, A, Henderson, L, Xu, P, O'Day, E, Rendak, R, Liao, WL, Cecchi, F, Hembrough, T, Schwartz, S, Szeto, C, Rustgi, AK, Wong, KK, Diehl, JA, Jensen, K, Graziano, F, Ruzzo, A, Fereshetian, S, Mertins, P, Carr, SA, Beroukhim, R, Nakamura, K, Oki, E, Watanabe, M, Baba, H, Imamura, Y, Catenacci, D & Bass, AJ 2018, 'Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition letter', Nature Medicine, vol. 24, no. 7, pp. 968-977. https://doi.org/10.1038/s41591-018-0022-x
Wong, Gabrielle S. ; Zhou, Jin ; Liu, Jie Bin ; Wu, Zhong ; Xu, Xinsen ; Li, Tianxia ; Xu, David ; Schumacher, Steven E. ; Puschhof, Jens ; McFarland, James ; Zou, Charles ; Dulak, Austin ; Henderson, Les ; Xu, Peng ; O'Day, Emily ; Rendak, Rachel ; Liao, Wei Li ; Cecchi, Fabiola ; Hembrough, Todd ; Schwartz, Sarit ; Szeto, Christopher ; Rustgi, Anil K. ; Wong, Kwok Kin ; Diehl, J. Alan ; Jensen, Karin ; Graziano, Francesco ; Ruzzo, Annamaria ; Fereshetian, Shaunt ; Mertins, Philipp ; Carr, Steven A. ; Beroukhim, Rameen ; Nakamura, Kenichi ; Oki, Eiji ; Watanabe, Masayuki ; Baba, Hideo ; Imamura, Yu ; Catenacci, Daniel ; Bass, Adam J. / Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition letter. In: Nature Medicine. 2018 ; Vol. 24, No. 7. pp. 968-977.
@article{553636eca47841a78b3bd52af4e6cc6c,
title = "Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition letter",
abstract = "The role of KRAS, when activated through canonical mutations, has been well established in cancer 1 . Here we explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations. These amplifications occur most commonly in esophageal, gastric and ovarian adenocarcinomas 2-4 . KRAS-amplified gastric cancer models show marked overexpression of the KRAS protein and are insensitive to MAPK blockade owing to their capacity to adaptively respond by rapidly increasing KRAS-GTP levels. Here we demonstrate that inhibition of the guanine-exchange factors SOS1 and SOS2 or the protein tyrosine phosphatase SHP2 can attenuate this adaptive process and that targeting these factors, both genetically and pharmacologically, can enhance the sensitivity of KRAS-amplified models to MEK inhibition in both in vitro and in vivo settings. These data demonstrate the relevance of copy-number amplification as a mechanism of KRAS activation, and uncover the therapeutic potential for targeting of these tumors through combined SHP2 and MEK inhibition.",
author = "Wong, {Gabrielle S.} and Jin Zhou and Liu, {Jie Bin} and Zhong Wu and Xinsen Xu and Tianxia Li and David Xu and Schumacher, {Steven E.} and Jens Puschhof and James McFarland and Charles Zou and Austin Dulak and Les Henderson and Peng Xu and Emily O'Day and Rachel Rendak and Liao, {Wei Li} and Fabiola Cecchi and Todd Hembrough and Sarit Schwartz and Christopher Szeto and Rustgi, {Anil K.} and Wong, {Kwok Kin} and Diehl, {J. Alan} and Karin Jensen and Francesco Graziano and Annamaria Ruzzo and Shaunt Fereshetian and Philipp Mertins and Carr, {Steven A.} and Rameen Beroukhim and Kenichi Nakamura and Eiji Oki and Masayuki Watanabe and Hideo Baba and Yu Imamura and Daniel Catenacci and Bass, {Adam J.}",
year = "2018",
month = "7",
day = "1",
doi = "10.1038/s41591-018-0022-x",
language = "English (US)",
volume = "24",
pages = "968--977",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition letter

AU - Wong, Gabrielle S.

AU - Zhou, Jin

AU - Liu, Jie Bin

AU - Wu, Zhong

AU - Xu, Xinsen

AU - Li, Tianxia

AU - Xu, David

AU - Schumacher, Steven E.

AU - Puschhof, Jens

AU - McFarland, James

AU - Zou, Charles

AU - Dulak, Austin

AU - Henderson, Les

AU - Xu, Peng

AU - O'Day, Emily

AU - Rendak, Rachel

AU - Liao, Wei Li

AU - Cecchi, Fabiola

AU - Hembrough, Todd

AU - Schwartz, Sarit

AU - Szeto, Christopher

AU - Rustgi, Anil K.

AU - Wong, Kwok Kin

AU - Diehl, J. Alan

AU - Jensen, Karin

AU - Graziano, Francesco

AU - Ruzzo, Annamaria

AU - Fereshetian, Shaunt

AU - Mertins, Philipp

AU - Carr, Steven A.

AU - Beroukhim, Rameen

AU - Nakamura, Kenichi

AU - Oki, Eiji

AU - Watanabe, Masayuki

AU - Baba, Hideo

AU - Imamura, Yu

AU - Catenacci, Daniel

AU - Bass, Adam J.

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The role of KRAS, when activated through canonical mutations, has been well established in cancer 1 . Here we explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations. These amplifications occur most commonly in esophageal, gastric and ovarian adenocarcinomas 2-4 . KRAS-amplified gastric cancer models show marked overexpression of the KRAS protein and are insensitive to MAPK blockade owing to their capacity to adaptively respond by rapidly increasing KRAS-GTP levels. Here we demonstrate that inhibition of the guanine-exchange factors SOS1 and SOS2 or the protein tyrosine phosphatase SHP2 can attenuate this adaptive process and that targeting these factors, both genetically and pharmacologically, can enhance the sensitivity of KRAS-amplified models to MEK inhibition in both in vitro and in vivo settings. These data demonstrate the relevance of copy-number amplification as a mechanism of KRAS activation, and uncover the therapeutic potential for targeting of these tumors through combined SHP2 and MEK inhibition.

AB - The role of KRAS, when activated through canonical mutations, has been well established in cancer 1 . Here we explore a secondary means of KRAS activation in cancer: focal high-level amplification of the KRAS gene in the absence of coding mutations. These amplifications occur most commonly in esophageal, gastric and ovarian adenocarcinomas 2-4 . KRAS-amplified gastric cancer models show marked overexpression of the KRAS protein and are insensitive to MAPK blockade owing to their capacity to adaptively respond by rapidly increasing KRAS-GTP levels. Here we demonstrate that inhibition of the guanine-exchange factors SOS1 and SOS2 or the protein tyrosine phosphatase SHP2 can attenuate this adaptive process and that targeting these factors, both genetically and pharmacologically, can enhance the sensitivity of KRAS-amplified models to MEK inhibition in both in vitro and in vivo settings. These data demonstrate the relevance of copy-number amplification as a mechanism of KRAS activation, and uncover the therapeutic potential for targeting of these tumors through combined SHP2 and MEK inhibition.

UR - http://www.scopus.com/inward/record.url?scp=85047828977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047828977&partnerID=8YFLogxK

U2 - 10.1038/s41591-018-0022-x

DO - 10.1038/s41591-018-0022-x

M3 - Article

C2 - 29808010

AN - SCOPUS:85047828977

VL - 24

SP - 968

EP - 977

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 7

ER -